Quarterly report pursuant to Section 13 or 15(d)

SEGMENT INFORMATION (Tables)

v3.24.0.1
SEGMENT INFORMATION (Tables)
3 Months Ended
Jan. 31, 2024
Segment Reporting [Abstract]  
SCHEDULE OF SEGMENT INFORMATION

    2024     2023  
    For the Three Months Ended
January 31,
 
    2024     2023  
Net loss:                
CAR-T Therapeutics   $ (1,525 )   $ (911 )
Cancer Vaccines     (1,756 )     (958 )
Anti-Viral Therapeutics     -       (482 )
Other     (9 )     (3 )
Total   $ (3,290 )   $ (2,354 )
                 
Total operating costs and expenses   $ 3,609     $ 2,556  
Less non-cash share-based compensation     (1,260 )     (1,063 )
Operating costs and expenses excluding non-cash share-based compensation   $ 2,349     $ 1,493  
Operating costs and expenses excluding non-cash
share based compensation expense:
               
CAR-T Therapeutics   $ 1,128     $ 598  
Cancer Vaccines     1,213       588  
Anti-Viral Therapeutics     -       305  
Other     8       2  
Total   $ 2,349     $ 1,493  

 

    January 31,
2024
    October 31,
2023
 
Total assets:                
CAR-T Therapeutics   $ 12,124     $ 7,523  
Cancer Vaccines     13,162       17,215  
Anti-Viral Therapeutics     -       700  
Other     86       84  
Total   $ 25,372     $ 25,522